Home / Biotech/Pharma

Biotech/Pharma

MediWound to Ring the NASDAQ Stock Market Closing Bell in Recognition of Burn Awareness Week מדיוונד יצלצל פעמון הסגירה בבורסת הנאסד"ק כחלק משבוע של מודעות לצריבה

MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced that Gal Cohen, MediWound’s Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell today (February 5, 2015) in ...

Read More »

Alcobra Ltd. Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Over-Allotment Option אלקוברה בע״מ מכריז על סגירת הנפקה של מניות רגילות

After its stock dropped over 80% last year with failed Phase III trial results, Alcobra has raised approximately $27.9 million in a public offering of ordinary shares. The full over allotment option was exercised by the underwriters: 975,000 of the 7.5 million ...

Read More »

Therapix Biosciences and Dekel Pharmaceuticals Sign Binding Term Sheet Outlining Licensing and Royalty Agreement תראפיקס ביוסיינסס בע"מ ודקל פארמסוטיקלס בע"מ חתמו על הסכם לרישוי ותמלוגים

Therapix Biosciences, a biopharma company focused on cannabinoid drugs, has signed a binding term sheet with Dekel Pharmaceuticals for the exclusive worldwide right to develop, manufacture and commercialize combination drug therapies based on Dekel’s technology. The technology is based on the “entourage effect” ...

Read More »

cCAM Biotherapeutics Receives FDA Approval to Initiate Phase 1 Trial for CM-24, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy סיקאם ביות'רפיוטיקס בע"מ קיבל את האישור ליזום ניסוי קליני לסרטן

First-in-human Phase 1 trial expected to commence in Q1 2015 MISGAV, Israel–(BUSINESS WIRE)–cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that it has received approval form the US Food and Drug ...

Read More »

Pluristem Granted Patent for Foundational Cell Harvesting Technology in South Africa פלוריסטם קיבל פטנט בדרום אפריקה לטכנולוגיה לקציר תאים

Patent Covers Methods for Using Vibration to Harvest Large Yields of Viable Cells Grown With Three-Dimensional Technology HAIFA, Israel, Jan. 6, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that ...

Read More »

Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications כן פייט ביופרמה מכריזה על אבני דרך לתרופות ב-4 אינדיקציות

Can-Fite BioPharma Ltd., an advanced clinical stage drug development company, announced its anticipated clinical milestones for 2015. Plans for Q1 include positive results to be released from a Phase II/III psoriasis trial for its lead drug candidate, CF101, and a commercial ...

Read More »

Chiasma Raising Millions Despite Roche Collaboration Debacle כיאזמה גייסה מיליוני דולרים למרות קריסתו של שיתוף הפעולה המתוכנן עם רוש

Jerusalem-based Chiasma has raised $33.8 million of a proposed $56.3 million round, despite cancellation of an approximately $595 million deal with global biotech Roche last summer. New funds were provided by a portfolio of investors including MPM Capital, Abingworth, 7-Med Health Ventures LP, ARCH Venture Partners and F2 and F3 Ventures. Chiasma has shown promise as a ...

Read More »

RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015 התחזית העסקית ואבני הדרך הצפוי של רדהיל ביופרמה ב2015

RedHill BioPharma Ltd., a biopharmaceutical company focused on the development and acquisition of late clinical-stage orally administered drugs for treating inflammatory and gastrointestinal diseases, announced selected key milestones and events anticipated in 2015. Upcoming milestones include: Top-line data from ongoing first Phase III study ...

Read More »

BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™ בריינסטורם מכריז על מחקר שהראה שנור-און מועיל קלינית לכמעט כל החולים

BrainStorm Cell Therapeutics Inc. announced positive results in its Phase IIa clinical trial of its NurOwn stem cell therapy technology for amyotrophic lateral sclerosis (ALS). 92% of the 14 subjects enrolled at Hadassah Medical Center experienced an improvement in the rate of ALS ...

Read More »